Biopharmaceutical Optimisation of β-Cyclodextrin Inclusion Compounds
- 12 Downloads
To improve the biopharmaceutical performance of the nonsteroidal anti-inflammatory drug piroxicam, inclusion compounds with β-cyclodextrin carrier have been prepared and studied for a wide range of chemical, physical and pharmaceutical properties.
Three bulk products were obtained, 2 by a process of freeze-drying (preparation A/1 and preparation A/2) and changing process parameters, and 1 by spray-drying (preparation B). The objective was to obtain tablets which provide a rapid-release dosage form of piroxicam.
Studies were conducted in vitro and in humans and compared tablets of the inclusion complex of piroxicam and β-cyclodextrin with marketed oral and parenteral dosage forms of piroxicam. Significant differences were found in plasma levels, maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC), confirming that biopharmaceutical optimisation of the complexes can be achieved, leading to an overall pattern of absorption which is better than those presented by standard, non-complexed formulations of piroxicam (capsules, and ampoules for intramuscular use).
Evidence for a correlation between the 2 main physicopharmaceutical variables (solubilisation kinetics of the complex and dissolution rate of the tablet) and biopharmaceutical performances support the development of the product.
KeywordsDissolution Rate Inclusion Complex Piroxicam Water Contact Angle Physical Mixture
Unable to display preview. Download preview PDF.
- Boscolo M, Carli F, Crimella T, et al. Evaluation on the suitability of differential scanning calorimetry in the preformulation stability screening. Drug Development and Industrial Pharmacy, in pressGoogle Scholar
- Eatough DJ, Christensen JJ, Izatt RM. Experiments in thermometric titrimetry and titration calorimetry. Brigham Young University Press, Provo, Utah, 1973Google Scholar
- Higuchi T, Connors K. Phase-solubility techniques. Advances in Analytical Chemistry and Instrumentation 4: 117–212, 1965Google Scholar
- Mihalic M, Hofman H, Kajfez F, Kuftinec J. Blazevic N, Zinic M. Physico-chemical and analytical characteristic of piroxicam. Acta Pharmaceutica Jugoslavica 32: 13–20, 1982Google Scholar
- Patoia L, Clausi G, Farroni F, Alberti P, Fugiani P, et al. Faecal blood loss, upper gastro-intestinal mucosal integrity and symptoms following piroxicam β-cyclodextrin, piroxicam and placebo administration: a comparative study. European Journal of Clinical Pharmacology, in pressGoogle Scholar
- Roos-Hoffet A. Characterization of β-cyclodextrin complexes. Proceeding of the 4th International Symposium on Cyclodextrins, Kluwer Academic Publishers, Dordrecht, 1988Google Scholar
- Szeijtli J. Cyclodextrins and their inclusion complexes, Academiai Kiado, Budapest, 1982Google Scholar
- Tokomura T, Tsushima Y, Tatsuishi K, Kayano M, Nachida Y, et al. Preparation of cinnarrizine/β-cyclodextrin inclusion complex by spray-drying method and the stability of complex in solid state. Yakuzaigaku 45: 1–6, 1985Google Scholar